Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Azacitidina")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Language

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 273

  • Page / 11
Export

Selection :

  • and

Dual antitumour effect of 5-azacytidine by inducing a breakdown of resistance-mediating factors and epigenetic modulationVENTURELLI, Sascha; BERGER, Alexander; FULDA, Simone et al.Gut. 2011, Vol 60, Num 2, pp 156-165, issn 0017-5749, 10 p.Article

Immunomodulatory effect of 5-azacytidine (5-azaC): potential role in the transplantation settingSANCHEZ-ABARCA, Luis I; GUTIERREZ-COSIO, Silvia; FLORES, Teresa et al.Blood. 2010, Vol 115, Num 1, pp 107-121, issn 0006-4971, 15 p.Article

5-Azacytidine facilitates osteogenic gene expression and differentiation of mesenchymal stem cells by alteration in DNA methylationZHOU, Guo-Shun; ZHANG, Xiao-Lei; WU, Jun-Ping et al.Cytotechnology (Dordrecht). 2009, Vol 60, Num 1-3, pp 11-22, issn 0920-9069, 12 p.Article

5 -Azacytidine -induced methyltransferase-DNA adducts block DNA replication in vivoKENNY KUO, H; GRIFFITH, Jack D; KREUZER, Kenneth N et al.Cancer research (Baltimore). 2007, Vol 67, Num 17, pp 8248-8254, issn 0008-5472, 7 p.Article

Frequencies of occurence of all human chromosomes in micronuclei from normal and 5-azacytidine-treated lymphocytes as revealed by chromosome paintingFAUTH, E; SCHERTHAN, H; ZANKL, H et al.Mutagenesis. 1998, Vol 13, Num 3, pp 235-241, issn 0267-8357Article

Novel L-amino acid ester prodrugs of azacitidine: Design, enzymatic synthesis and the investigation of release behaviorFAN XU; MING ZHANG; QI WU et al.Journal of molecular catalysis. B, Enzymatic. 2014, Vol 105, pp 49-57, issn 1381-1177, 9 p.Article

Approval summary : Azacitidine for treatment of myelodysplastic syndrome subtypesKAMINSKAS, Edvardas; FARRELL, Ann; WANG, Yong-Cheng et al.Clinical cancer research. 2005, Vol 11, Num 10, pp 3604-3608, issn 1078-0432, 5 p.Article

Aerosolised 5-azacytidine suppresses tumour growth and reprogrammes the epigenome in an orthotopic lung cancer modelREED, M. D; TELLEZ, C. S; GRIMES, M. J et al.British journal of cancer. 2013, Vol 109, Num 7, pp 1775-1781, issn 0007-0920, 7 p.Article

Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisisGHEZ, David; MICOL, Jean-Baptiste; CASTAIGNE, Sylvie et al.European journal of cancer (1990). 2013, Vol 49, Num 17, pp 3666-3670, issn 0959-8049, 5 p.Article

Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromesLEE, Yun-Gyoo; KIM, Inho; PARK, Yong et al.British journal of haematology. 2013, Vol 161, Num 3, pp 339-347, issn 0007-1048, 9 p.Article

DNA Methylation Inhibitors, 5-azacytidine and Zebularine Potentiate the Transdifferentiation of Rat Bone Marrow Mesenchymal Stem Cells into CardiomyocytesNAEEM, Nadia; HANEEF, Kanwal; KABIR, Nurul et al.Cardiovascular therapeutics (Print). 2013, Vol 31, Num 4, pp 201-209, issn 1755-5914, 9 p.Article

Successful treatment by azacitidine therapy of intestinal Behçet's disease associated with myelodysplastic syndromeTANAKA, Hiroaki; SHIMIZU, Naomi; TAKAGI, Toshiyuki et al.International journal of hematology. 2013, Vol 97, Num 4, pp 520-524, issn 0925-5710, 5 p.Article

TGFβ1 contributes to cardiomyogenic-like differentiation of human bone marrow mesenchymal stem cellsMOHANTY, Sujata; BOSE, Sushmita; KRISHAN GOPAL JAIN et al.International journal of cardiology. 2013, Vol 163, Num 1, pp 93-99, issn 0167-5273, 7 p.Article

Chemical stability of azacitidine suspensions for injection after cold-chain reconstitution of powder and storageLEGERON, Rachel; XUEREB, Fabien; DJABAROUTI, Sarah et al.American journal of health-system pharmacy. 2013, Vol 70, Num 23, pp 2137-2142, issn 1079-2082, 6 p.Article

Antiproliferative and Antitumor Effects of Azacitidine Against the Human Myelodysplastic Syndrome Cell Line SKM-1KIMURA, Sachie; KURAMOTO, Kazuya; HOMAN, Junko et al.Anticancer research. 2012, Vol 32, Num 3, pp 795-798, issn 0250-7005, 4 p.Article

Combination strategies in myelodysplastic syndromesORNSTEIN, Moshe C; SEKERES, Mikkael A.International journal of hematology. 2012, Vol 95, Num 1, pp 26-33, issn 0925-5710, 8 p.Article

Optimizing hypomethylating agents in myelodysplastic syndromesITZYKSON, Raphael; FENAUX, Pierre.Current opinion in hematology. 2012, Vol 19, Num 2, pp 65-70, issn 1065-6251, 6 p.Article

Promoter methylation of MGMT, MLH1 and RASSF1A tumor suppressor genes in head and neck squamous cell carcinoma: Pharmacological genome demethylation reduces proliferation of head and neck squamous carcinoma cellsKOUTSIMPELAS, Dimitrios; PONGSAPICH, Warut; HEINRICH, Ulf et al.Oncology reports. 2012, Vol 27, Num 4, pp 1135-1141, issn 1021-335X, 7 p.Article

Treatment of relapsed myelodysplastic syndrome following double umbilical cord blood transplantation with interferon alpha and 5-azacytidineSAMUELSON, Clare; DALLEY, Christopher; EZAYDI, Yousef et al.British journal of haematology. 2012, Vol 159, Num 5, pp 602-604, issn 0007-1048, 3 p.Article

Treatment of Advanced Myelodysplastic Syndrome With Demethylating Agents: AzacitidineADES, Lionel; ITZYKSON, Raphael; FENAUX, Pierre et al.Seminars in hematology. 2012, Vol 49, Num 4, pp 323-329, issn 0037-1963, 7 p.Article

Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapseSOCKEL, Katja; WERMKE, Martin; RADKE, Jörgen et al.Haematologica (Roma). 2011, Vol 96, Num 10, pp 1568-1570, issn 0390-6078, 3 p.Article

Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidineITZYKSON, R; THEPOT, S; GARDIN, C et al.Leukemia. 2011, Vol 25, Num 7, pp 1207-1209, issn 0887-6924, 3 p.Article

Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic SyndromesSILVERMAN, Lewis R; FENAUX, Pierre; MUFTI, Ghulam J et al.Cancer. 2011, Vol 117, Num 12, pp 2697-2702, issn 0008-543X, 6 p.Article

Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemiasITZYKSON, R; KOSMIDER, O; PREUDHOMME, C et al.Leukemia. 2011, Vol 25, Num 7, pp 1147-1152, issn 0887-6924, 6 p.Article

Influence of 5'-azacitidine on promoting recovery of cell competence for shoot organogenesis in ArabidopsisTOKUJI, Yoshihiko; TAKANO, Shou; TONOMURA, Motoki et al.Plant cell, tissue and organ culture. 2011, Vol 106, Num 2, pp 289-297, issn 0167-6857, 9 p.Article

  • Page / 11